, wherein VAC and VFA are velocities of opening and closure of mitral valve indicative of atrium's systole, and LABV is left atrium's beat volume. Cardiologist proceeds upon assumption that if factor K value is equal to, or greater than 6, it is verapamyl that is clinically effective, whereas at factor K value of below 6 it is dilthiazem that is clinically useful. EFFECT: proposed method can be used to evaluate clinical efficiency of calcium antagonists in patients affected with hypertrophic cardiomyopathy, thereby showing rational approach to their treatment."/>
公开/公告号RU2078536C1
专利类型
公开/公告日1997-05-10
原文格式PDF
申请/专利号RU19930045757
发明设计人 VORONKOV LEONID GEORGIEVICH;YANOVSKIJ GEORGIJ VIKTOROVICH;EFIMTSEVA TATYANA KONSTANTINOVNA;KOVTUN LYUDMILA IVANOVNA;
申请日1993-09-02
分类号A61B5/02;
国家 RU
入库时间 2022-08-22 03:15:56